Olanzapine therapy in anorexia nervosa: Psychobiological effects

International Clinical Psychopharmacology

Volumn 22, Issue 4, 2007, Pages 197-204

  Brambilla, Francesca ^a,g,h   Garcia, Cristina Segura ^b   Fassino, Secondo ^c   Daga, Giovanni Abbate ^c   Favaro, Angela ^d   Santonastaso, Paolo ^d   Ramaciotti, Carla ^e   Bondi, Emilia ^e   Mellado, Carmen ^a,g   Borriello, Renata ^f   Monteleone, Palmiero ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Centro di Psiconeuroendocrinologia   (Italy)

Author keywords

Anorexia nervosa; Cognitive behavioral therapy; Homovanillic acid; Olanzapine

Indexed keywords

HOMOVANILLIC ACID; OLANZAPINE; PLACEBO;

ADULT; ANOREXIA NERVOSA; ARTICLE; BEHAVIOR THERAPY; BINGE EATING DISORDER; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOBIOLOGY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE;

ADULT; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HOMOVANILLIC ACID; HUMANS;

EID: 34249007481     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328080ca31     Document Type: Article

References (86)

1. Allison DB, Casey D (2001). Antypsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 (Suppl 7):22-31.
2. American Psychiatric Association (1994.) Diagnostic and statistical manual of mental disorders. 4th ed. Washington District Columbia.
3. Attia E, Kaplan AS, Schroeder L, Federici A, Staab R (2005.) Atypical antipsychotic medication in anorexia nervosa. Toronto: Eating Disorders Research Society congress, abstract book.
4. Backer RW, Brown EB, Schuh LM (2003). Patterns of weight gain in bipolar patients treated with olanzapine or divalproex. Biol Psychiatry 53:133S-134S.
5. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, et al. (2004). An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 65:1480-1482.
6. Bernardo M, Parellada E, Lomena F, Catafau AM, Font M, Gomez JC, et al. (2001). Double-blind olanzapine vs haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res 107:87-98.
7. BMDP (1985). Statistical Software. Berkeley, USA: University of California Press.
8. Boachie A, Goldfield GS, Spettique W (2003). Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord 33:98-103.
9. Bosanac P, Burrows G, Norman T (2005). Olanzapine in anorexia nervosa. Aust N Z J Psychiatry 37:494.
10. Bowers MB, Mariera CM Jr, Greenfeld DG (1994). Elevated plasma monoamine metabolites in eating disorders. Psychiatry Res 52:11-16.
11. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D (2001). Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 26:393-409.
12. Bruins-Slot L, Gorwood P, Bouvard M, Blot P, Adès J, Feingold J, et al. (1998). Lack of association between Anorexia Nervosa and D3 Dopamine receptor gene. Biol Psychiatry 43:76-78.
13. Buss AH, Durkee A (1957). An inventory for assessing different kinds of hostility. J Consult Psychology 21:343-349.
14. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NWW, Wong DT (1997). In vitro and in vivo biochemistry of olanzapine: a novel atypical antipsychotic drug. J Clin Psychiatry 58:28-36.
15. Carver AE, Miller S, Hagman J, Siegel E (2002). The use of risperidone for the treatment of anorexia nervosa. Boston: Acad Eat Disord Annual Meeting, abstract book.
16. Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, et al. (2003). Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord 33:172-177.
17. Castro J, Deulofeu R, Casolà V, Puig J, Bernardo M (2004). Plasma homovanillic acid and nutritional and psychopathological parameters in adolescents with anorexia nervosa. Int J Eat Dis 35:458-459.
18. Cloninger C, Przybeck T, Svarkic D, Wetzel R (1994). The temperament and character inventory (TCI): a guide to its development and use. St Louis, Missouri: Center for Psychobiology of Personality, Washington University.
19. Coates JW (2000). Olanzpine in the treatment of anorexia nervosa. Br J Psychiatry 25:S92.
20. Dally A (1966). Treatment and outcome of anorexia nervosa. Br Med 517:793-795.
21. Dare C, Russel G, Treasure J, Dodge L (2001). Psychological therapies for adults with anorexia nervosa. Br J Psychiatry 178:216-221.
22. De Zwaan M, Roerig J (2003). Pharmacological treatment of eating disorders. In: Maj M, Halmi K, Lopez-Ibor JJ, Sartorius N, editors. Eating disorders. Wiley J, Chichester, West Sussex. pp. 223-314.
23. Ebert MH, Kaye WH, Gold PW (1984). Neurotransmitter metabolism in anorexia nervosa. In: Pirke KM, Ploog D, editors. The psychobiology of anorexia nervosa. Springer-Verlag, Berlin, Heidelberg. pp. 58-72.
24. Ercan ES, Copkunol H, Cykoethlu S, Varan A (2003). Olanxapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol 18:401-403.
25. Fassino S, Leombruni P, Abbate Daga G, Brustolin A, Migliaretti G, Cavallo F, et al. (2002). Efficacy of citalopram in anorexia nervosa. Eur Neuropsychopharmacol 12:453-459.
26. Fava M, Copeland PM, Schweiger U, Herzog DB (1989). Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am J Psychiatry 146:963-971.
27. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured clinical interview for DSM-IV axis I disorders (Patient ed., Version 2.0 8/98 revision) New York: New York State Psychiatric Institute.
28. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, et al. (2005). Increased Dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11-C] raclopride. Biol Psychiatry 58:908-912.
29. Garner DM (1991). The eating disorder inventory-2. Odessa FL; USA Psychological Assessment Resources.
30. Garner DM, Vitousek K, Pike K (1997). Cognitive-behavioral therapy for anorexia nervosa. In: Garner DM, Garfinkel PE, editors. Handbook of treatment for eating disorders. New York: Guilford Press; pp. 94-144.
31. Gaskill JA, Treat TA, McCabe EB, Marcus MD (2001). Does olanzapine affect the rate of weight gane among inpatients with eating disorders? Int J Eat Disord Review 12:1-2.
32. Goudie AJ, Smith JA, Halford JCG (2002). Characterization of olanzapine-induced weight gain in rats. J Psychopharmacology 16:291-296.
33. Gerner RH, Cohen DJ, Fairbanks L, Anderson GM, Young JG, Scheinin M, et al. (1984). CNS neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry 141:1441-1444.
34. Gillberg C (1983). Low dopamine and serotonin levels in anorexia nervosa. Am J Psychiatry 140:948-949.
35. Glazer WM, Bowers MB, Charney DS, Henninger GR (1990). The effect of neuroleptic discontinuation on psychopathology, involuntary movements and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry. 26:224-233.
36. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, et al. (2002). Sex differences in clinical response to olanzapine compared with haloperidol. Psychiat Res 110:27-38.
37. Gowers S, Bryant-Waugh R (2004). Management of child and adolescent eating disorders: the current evidence base and future directions. J Child Psychol Psychiatry 45:63-83.
38. Halmi KA, Sherman BM (1977). Dopaminergic and serotoninergic regulation of growth hormone secretion in anorexia nervosa. Psychopharmacol Bull 13:63-65.
39. Halmi KA, Owen WP, Lasley E, Stokes P (1983). Dopaminergic regulation in anorexia nervosa. Int J Eat Dis 2:129-133.
40. Halmi KA (1996). The psychobiology of eating behavior in anorexia nervosa. Psychiat Res 62:23-29.
41. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 2:56-62.
42. Hansen L (1999). Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 175:592.
43. Hillebrand JJG, van Elburg AA, Kas MJH, van England H, Adan RAH (2005). Olanzapine reduces physical activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 58:651-657.
44. Jensen VS, Mejihede A (2002). Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 177:87.
45. Kaye WH, Ebert MH, Raleigh M, Raymond Lake C (1984). Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatry 41:350-355.
46. Kaye WH, Rubinow D, Gwirtsman HE, George DT, Jimerson DC, Gold PW (1988). CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic-pituitary-adrenal cortical axis. Psycho-neuroendocrinology 13:265-272.
47. Kaye WH, Gendall K, Strober M (1998). Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 44:825-838.
48. Kaye WH, Frank GKW, McConaha C (1999). Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 21:503-506.
49. Kaye WH, Frank GK, Bailer UF, Henry SE (2005). Neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems. Int J Eat Disord 37:S15-S19.
50. Kim SS (2003). Role of fluoxetine in anorexia nervosa. Ann Pharmacotherapy 37:890-892.
51. Klump KL, Gobrogge KL (2005). A review and primer of molecular genetic studies of anorexia nervosa. In J Eat Disord 37:541-542.
52. Kronvall P, Wallin U, Amylon B (2001). Fluoxetine-olanzpine treatment in severe anorexia nervosa with co-morbidity. ECED congress, Barcelona 2001, abstracts.
53. La Via MC, Gray N, Kaye WH (2000). Case report of olanzapine in treatment of anorexia nervosa. Int J Eat Disord 27:363-366.
54. Lawrence AD, Dowson J, Foxall GL, Summerfield R, Robbins TW, Sahakian BJ (2003). Impaired visual discrimination learning in anorexia nervosa. Appetite 40:85-89.
55. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190.
56. Lipkovich I, Ahmed S, Ahl J, Hardy T, Haldane D, Baker RW, et al. (2004). Early weight gain as a predictor of substantial weight: results from seven studies of olanzapine for the treatment of bipolar disorder. Biol Psychiatry 55:181S.
57. Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, et al. (2003). Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord 33:234-237.
58. Mangano A, Dattola G, Polito F, Tripodi C, Suraci FC, Nucera A (2004). Therapeutic potentiality of olanzapine in the treatment of anorexia nervosa [In italian]. Ital J Psychopathology 8:249.
59. Mazure CM, Halmi KA, Sunday SR, Romano SJ, Einhorn AM (1994). The Yale-Brown-Cornell Eating Disorder Scale: development, use, reliability and validity. J Psychiatr Res 28:425-445.
60. Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittman RW (2001). Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Europ Child Adolesc Psychiatry 10:151-157.
61. Menaster M (2005). Use of olanzapine in anorexia nervosa. J Clin Psychiatry 66:654-655.
62. Mitchell JE, De Zwaan M, Roerig JL (2003). Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2:17-29.
63. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont F (2005). Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 13:72-75.
64. Newcomer JW (2005). Clinical considerations in selecting and using atypical antipsychotics. CNS Spectrum 10:12-19.
65. Newman Tocker J (2000). Risperidone in Anorexia Nervosa. J Am Acad Child Adolesc Psychiatry 39:941-942.
66. Odink J, Thissen JTNM, Zeegers JH, Schreurs WHP (1986). Diurnal variations in age and sex dependency on the excretion of free catecholamines, homovanillic acid, vanilmandelic acid and 5-hydroxyindole-3-acetic acid in urine of children and adolescents. Bio Amines 3:257-265.
67. Owen WP, Halmi KA, Lasley E, Stokes P (1983). Dopamine regulation n anorexia nervosa. Psychopharmacol Bull 19:578-581.
68. Pederson KJ, Roerig JL, Mitchell JE (2003). Towards the pharmacotherapy of eating disorders. Expert Opinion Pharmacotherapy 4:1659-1678.
69. Pickar D, Breier A, Doran AR, Wolkowitz OM, Patio CN, Potter WZ (1990). Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 47:641-648.
70. Powers PS, Santana CA, Bannon YS (2002). Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 32:146-154.
71. Reynold GP, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polimorphism. The Lancet 359:2086-2087.
72. Riederer P, Toifl K, Kruzik P (1982). Excretion of biogenic amine metabolites in anorexia nervosa. Clin Chem Acta 123:27-32.
73. Ridley-Siegert D (2000). Anorexia nervosa: treatment with olanzapine. Br J Psychiat 177:87.
74. Roerig JL, Mitchell JE, De Zwaan M, Crosby RD, Gosnell BA, Steffen KJ, et al. (2005). A comparison of the effects of olanzapine and placebo on eating behaviors. J Clin Psychopharmacol 25:413-418.
75. Ruggero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, Mantero M, et al. (2001). A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progr Neuropsychopharmacol Biol Psychiatry 25:1049-1059.
76. Russell GF, Checkley SA, Robinson PH (1986). The limited role of drugs in the treatment of anorexia and bulimia nervosa. In: Carruba MO, Blundell JE, editors. Pharmacology of Eating Disorders. New York: Raven Press; pp. 151-167.
77. Rybakovski F, Slopien A, Dmitrzak-Weglarz M, Hauser J, Rajewski A (2004). Polymorphism in dopamine D1 receptor gene is associated with harm-avoidance in anorexia nervosa patients and controls. Eating Disorders Research Society congress, Amsterdam 2004.
78. Santonastaso P, Friederici S, Favaro A (2001). Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol 11:143-150.
79. Scheepers FE, Gispen-DeWied C, Westenberg HG, Kahn RS (2001). The effect of olanzapine treatment on monoamino metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25:467-475.
80. Strober M, Freeman R, Lampert C, Diamond J, Kaye WH (2000). Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. Am J Psychiatry 157:393-401.
81. Urwin RE, Bennets B, Wilcken B, Lampopoulos B, Beumont P, Clarke S, et al. (2002). Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region. Mol Psychiatry 7:652-657.
82. Van Binsbergen CJM, Odink J, van der Beek EJ, Westenberg HMG, Coeling Bennink HJT (1991). Biogenic amines in anorexia nervosa: circadian rhythm in urinary excretion and influence of posture and physical task load on plasma catecholamines. Psychosom Med 53:440-452.
83. Vandereyken W, Pierlot R (1982). Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled cross-over study. Acta Psychiat Scand 66:445-450.
84. Vandereyken W (1984). Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo controlled study with sulpiride. Br J Psychiatry 144:288-292.
85. Wilson TG (2003). Psychological interventions for eating disorders. In: Maj M, Halmi K, Lopez-Ibor JJ, Sartorius N, editors. Eating disorders. Wiley, Chichester, West Sussex, pp. 315-382.
86. Zhang ZJ, Peet M, Ramchand CN, Shah S, Reynolds GP (2001). Plasma homovanillic acid in untreated schizophrenia: relationship with symptomatology and sex. J Psychiat Res 35:23-28.